Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Fidaxomicin may exhibit cross-reactivity in patients with known macrolide allergies. In this analysis, compared to patients without macrolide allergies, the odds of fidaxomicin allergy were 2.31, 8.37, and 1.58 times higher in patients with azithromycin, clarithromycin, and erythromycin allergies, respectively; the absolute risk of fidaxomicin allergy was 0.033, 0.01, and 0.039 in patients with azithromycin, clarithromycin, and erythromycin allergies, respectively. The highest risk of anaphylaxis and angioedema was observed within 1 year of a non-fidaxomicin macrolide allergy.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11963595 | PMC |
| http://dx.doi.org/10.1128/aac.01924-24 | DOI Listing |
Publication Analysis
Top Keywords
fidaxomicin allergy
12
patients macrolide
12
macrolide allergies
12
patients azithromycin
8
azithromycin clarithromycin
8
clarithromycin erythromycin
8
erythromycin allergies
8
patients
5
allergies
5
incidence fidaxomicin
4